Compare Progressive Corp (PGR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs GeneDx Holdings Corp — how do they compare? Progressive Corp trades at $217.43 (market cap $126.95B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Progressive Corp is far larger — about 62.8× GeneDx Holdings Corp's market cap, and Progressive Corp pays a 0.18% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and GeneDx Holdings Corp for 19 Days on average.
| PGR | WGS | |
|---|---|---|
Market Cap | $126.95B | $2.02B |
Volume | 2,749,438 | 734,640 |
Sector | Financials | Health |
52-Week High | $242.16 | $167.51 |
52-Week Low | $190.40 | $34.51 |
Typical Hold Time | 81 Days | 19 Days |
Enterprise Value | $135.16B | $2.05B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGR trades at $218.73, up 2.15% on the day, with a bullish technical signal and strong fundamentals. Revenue has grown from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. The stock is supported by a consensus price target of $222.23 and positive analyst sentiment, though RSI levels suggest some near-term overbought conditions.
The outlook for PGR is positive, driven by consistent earnings beats and robust profitability metrics like a 34.94% ROE. Risks include competitive pressures in personal auto insurance and potential market volatility. The stock offers a solid investment opportunity with upside to the price target, but investors should monitor underwriting discipline amid industry competition.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
